The number of CD163 and CD206 positive cells was increased in prostate cancer tissues induced by intraprostatic injection of LNCaP cells stably transfected with SFMBT2 shRNA and in prostate cancer tissues of patients (Figure 2D,E). This evidence concerns the gene CD163 and prostate cancer.